Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
28 hedge funds and large institutions have $143M invested in Eagle Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
280% more capital invested
Capital invested by funds: $37.6M → $143M (+$105M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
4% more funds holding
Funds holding: 27 → 28 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GE
General Electric
Evendale,
Ohio
|
+$12M |
| 2 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$3.61M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$2.56M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$1.69M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.26M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$582K |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$306K |
| 4 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$167K |
| 5 |
D.E. Shaw & Co
New York
|
-$102K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $9K | – | – | – |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | +$2.55K | +200 | +67% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $4K | -$21.7K | -1,699 | -86% |
|
|
FCM
29
Farallon Capital Management
San Francisco,
California
| – | -$1.26M | -100,000 | Closed |
|
|
BPC
30
Banque Pictet & Cie
Geneva 73,
Switzerland
| – | -$167K | -13,209 | Closed |
|
|
NFG
31
Next Financial Group
Houston,
Texas
| – | -$32K | -2,500 | Closed |
|
32
BNP Paribas Financial Markets
Paris,
France
| – | -$1.34K | -106 | Closed |
|
|
PCM
33
Prelude Capital Management
New York
| – | -$1K | -100 | Closed |
|
34
Barclays
London,
United Kingdom
| – | -$1K | -42 | Closed |
|
EGRX Hedge Fund Activity: Q4 2014 in Review
28 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2014, worth a combined $143M — up 280% from $37.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EGRX positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was General Electric, opening a new position worth an estimated $12M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $1.26M sold.
- 28 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2014, up from 27 in Q3 2014.
- Funds reported $143M of Eagle Pharmaceuticals, Inc. stock for Q4 2014, up 280% quarter-over-quarter.
- 9 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2014 and 7 closed out, a net change of +2 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2014 was General Electric, an estimated $12M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2014 was Farallon Capital Management, an estimated $1.26M sold.
Based on aggregated 13F filings for Q4 2014.